Consistent with patient-derived primary lung cancer cells (ELC12, ELC16, ELC17, and ELC20) and lung cancer cell lines (H460 and A549), most of them exhibited an upregulation of HDAC6 protein expression compared with normal lung epithelial BEAS-2B cells (Fig. 1E), suggesting that HDAC6 is a potential therapeutic target in lung adenocarcinoma. The gene discussed is HDAC6; the disease is lung adenocarcinoma.